NC-ARETEIA-THERAPEUTICS
13.2.2024 13:28:30 CET | Business Wire | Press release
Areteia Therapeutics, Inc. (“Areteia”) today announced $75 million in additional Series A financing to support expansion of the current Phase III development program of dexpramipexole in eosinophilic asthma, bringing total Series A funding to $425 million. Viking Global Investors and Marshall Wace join the original syndicate of investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners.
The additional capital raised will fund significant expansion of the ongoing Phase III program, to include adding clinical development in Japan along with several additional global markets, expansion of manufacturing activities and additional life-cycle management including development of a once daily formulation.
“We are delighted that leading biotech investors like Viking Global Investors and Marshall Wace have joined the syndicate. Their investment in Areteia further deepens our already strong capitalization position,” said Jorge Bartolome, President and Chief Executive Officer of Areteia. “We are pleased with the strong demand in this investment expansion round as our phase III program in eosinophilic asthma continues to make excellent progress.”
About Areteia Therapeutics
Areteia Therapeutics, Inc. (areteiatx.com) is a clinical stage biotechnology company whose purpose is to develop and deliver novel Inflammation and Immunology therapies that put respiratory patients in better control of their disease and back in control of their lives. Our initial focus is developing the first potential oral drug for severe eosinophilic asthma.
Areteia’s lead drug candidate is dexpramipexole, and if approved, will be a first-in-class oral eosinophil maturation inhibitor that targets eosinophilic inflammation by lowering blood and tissue eosinophils.
Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, committed to invest up to $350 million in Series A financing to establish Areteia and advance dexpramipexole through Phase III clinical trials, secure commercial supply, and pursue potential next-generation medicines. $75 million in expanded financing has now been committed by Viking Global Investors, Marshall Wace and the original syndicate. As a result, the Series A total financing now commits up to $425 million.
Areteia has initiated late-stage development of dexpramipexole in eosinophilic asthma, including three Phase III clinical trials in partnership with Population Health Partners’ development unit, Validae Health.
About Dexpramipexole
Dexpramipexole is an oral small molecule eosinophil lowering drug currently in Phase III development for eosinophilic asthma. Dexpramipexole inhibits the maturation of eosinophils in the bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels. Most recently in a Phase II study in patients with moderate-to-severe eosinophilic asthma, treatment with dexpramipexole resulted in a significant, dose-dependent reduction in blood absolute eosinophil count at all doses tested compared to placebo. Dexpramipexole was well tolerated in the trial, with adverse events balanced across treatment and placebo groups, no serious adverse events, and no adverse events leading to discontinuation.
About Eosinophilic Asthma
Asthma disrupts the lives of more than a quarter of a billion people worldwide. More than half of asthma patients have eosinophilic asthma, which is driven by an oversupply of eosinophils, a type of white blood cell, in blood and tissue. By inhibiting the maturation of eosinophils, oral dexpramipexole acts to lower eosinophils. Similarly, currently approved injectable anti-IL-5/5R biologic therapies provide clinical benefit through eosinophil lowering. The asthma biologic market is valued today at around $8 billion, with IL-5 biologic therapies approaching $4 billion of that figure. If approved as a first-to-market oral, dexpramipexole could provide a compelling alternative to injectable biologics, and could potentially expand the use of targeted therapy to address Type 2 eosinophilic inflammation in asthma.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240213672000/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mouser Explores the Newest Computing Technologies Beyond Moore's Law in its Technology Series10.11.2026 16:12:00 CET | Press release
Mouser Electronics, Inc., the authorized global distributor with the newest electronic components and industrial automation products, today announced the latest installment of its Empowering Innovation Together (EIT) technology series, Moving Beyond Moore's Law. The series explores how engineers are advancing computing performance as traditional semiconductor scaling approaches its physical limits, from chiplets and advanced packaging to silicon photonics and emerging transistor technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261006980414/en/ Explore what comes after Moore's Law as the industry seeks new paths to computing performance. As a key driver of semiconductor advancement, Moore's Law has served as a roadmap for the industry, describing the trend of transistor counts on integrated circuits doubling approximately every two years. With conventional silicon transistors becoming increasingly difficult to shr
Netceed appoints Eric Updyke as Group CEO10.11.2026 15:15:00 CET | Press release
Netceed, a global leader in delivering supply chain solutions across broadband, data center and energy infrastructure, today announced the appointment of Eric Updyke as Group CEO, effective 10th November, 2026. He succeeds Alper Türken, who will step down as CEO on 10th November, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110492065/en/ Netceed appoints Eric Updyke as Group CEO Eric brings more than 35 years of leadership experience in communications and technology infrastructure. Most recently, he served as CEO of Spirent Communications plc from 2019 to 2025. At Spirent, he led the company's shift from a hardware-centric vendor to a solutions provider built on software, automation and services. He also expanded the business into new sectors, including AI data center providers, and guided it through a strategic sale, culminating in its $1.5 billion acquisition by Keysight Technologies in 2025. Before Spirent, Eri
Nearly Nine in 10 Private Capital GPs Face Data Validation Challenges10.11.2026 15:00:00 CET | Press release
88% of GPs say finance and operations teams spend 11% to 50% of their time validating, reconciling, recalculating, or recreating administrator outputs70% of GPs are targeting outsourced or strategic co-sourced operating models, while 97% of LPs expect outsourcing to specialist providers to increase74% of LPs identify IT systems and cybersecurity as important to operational due diligence, while 59% want a documented AI and data governance framework shared during due diligence Nearly nine in 10 (88%) of private capital general partners (GPs) surveyed say their finance and operations teams spend between 11% and 50% of their time validating, reconciling, recalculating or recreating administrator outputs, according to new research from CSC, the leading provider of global business administration and compliance solutions¹. CSC surveyed more than 300 GPs and 200 limited partners (LPs) across North America, Europe, the U.K., and Asia Pacific. The report, Future Private Capital CFO 2026, examine
80% of IT Leaders Say the Digital Workplace Is Critical to AI Success, Yet Only 10% Have Fundamentally Redesigned It, Lenovo Research Finds10.11.2026 15:00:00 CET | Press release
Global study of 1,200 IT leaders identifies five connected dimensions of workplace readiness and shows where organizations can focus to turn AI ambition into measurable business value Eight in ten IT decision makers say the digital workplace is critical to successful AI-led transformation, yet only 10% report fundamentally redesigning it for AI, according to Lenovo’s sixth Work Reborn report, The AI-ready workplace. The findings expose a significant gap between deploying AI tools and the operating capabilities needed to integrate them into how work gets done across an organization. The report frames workplace readiness as a connected system spanning people, workflows, technology, support and governance, with each contributing to how enterprises translate AI ambition into business outcomes at scale. Based on an August 2026 survey of 1,200 IT leaders at organizations with at least 1,000 employees across 12 countries, the report examines the workplace conditions needed to translate AI dep
The $63.4 Billion Innovation Drain: Study Finds Unexpected Tech Costs Force Cuts into AI Investment and Hiring10.11.2026 15:00:00 CET | Press release
New economic research reveals how unpredictable infrastructure costs are constraining innovation, with potential savings that could support more than 111,000 jobs and generate $20.4 billion in long-term growthAI/ML infrastructure overspend is the most of any technology category at 37% ($23.4bn) of the total, and nearly twice as hard to forecast84% of organizations made at least one cost-driven trade-off over the past year Businesses across eight major economies incur $63.4 billion annually in technology infrastructure overspend attributable to opaque, unpredictable or difficult-to-forecast provider charges, forcing companies to scale back investments in artificial intelligence, hiring and new product development, according to new economic research from the Centre for Economics and Business Research (CEBR), commissioned by Wasabi Technologies. The overspend reflects infrastructure provider charges businesses could not forecast, rather than their own planned usage. AI and machine learnin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom